In this issue of Nature two groups present independent genomic analyses on ependymomas, a type of tumour that occurs throughout the nervous system, but most commonly in the hindbrain in children. Mack et al. found a low overall mutation rate and no significant recurrent mutations in 47 hindbrain ependymomas. But posterior fossa group B tumours, a subgroup found predominantly in infants and associated with poor prognosis, were distinguished by a CpG island methylator phenotype. This subgroup is shown to be susceptible to various compounds that target epigenetic modifications, including an EZH2 inhibitor that showed efficacy in a mouse xenograft model. Parker et al.found the C11orf95–RELA fusion gene in about 70% of supratentorial tumours, but not in other ependymoma subgroups. The gene fusions arise through chromothripsis and lead to the expression of a fusion protein that constitutively activates NF-KB signalling. In a mouse model, expression of C11orf95–RELA in neural stem cells leads to the formation of brain tumours. These findings identify NF-KB signalling as a possible therapeutic target in patients with this type of ependymoma.
- Tumours outside the mutation box (News & Views p438, doi: 10.1038/nature13061)
- Epigenomic alterations define lethal CIMP-positive ependymomas of infancy (Article p445, doi: 10.1038/nature13108)
- C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma (Article p451, doi: 10.1038/nature13109)
Recent Hot Topics
Sign up for Nature Research e-alerts to get the lastest research in your inbox every week.